Antiplatelet therapy in atherosclerotic cardiovascular disease

Clinical Therapeutics

Volumn 20, Issue SUPPL.2, 1998, Pages

  Gonzalez, Edgar R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet therapy; Atherosclerosis; CAPRIE studyr; Clopidogrel

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; PRIMARY PREVENTION; TREATMENT PLANNING;

ARTERIOSCLEROSIS; CLINICAL TRIALS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBOSIS;

EID: 0031832030     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80028-3     Document Type: Article

References (64)

1. Schafer AI. Antiplatelet therapy. Am J Med. 1996;101:199-209.
2. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355-1374.
3. Davies MJ. Pathology of arterial thrombosis. Br Med Bull. 1994;50:789-802.
4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92: 657-671.
5. Ferguson JJ. American College of Cardiology 45th Annual Scientific Session, Orlando, Florida. March 24-27, 1996. Circulation. 1996;94:1-5.
6. Timmons S, Kloczewiak M, Hawiger J. ADP-dependent common receptor mechanism for binding of von Willebrand factor and fibrinogen to human platelets. Proc Natl Acad Sci USA. 1984;81:4935-4939.
7. Wu KK. Platelet activation mechanisms and markers in arterial thrombosis. J Intern Med. 1996;239:17-34.
8. Schafer AI. Aspirin and antiplatelet agents in cardiovascular disease. In: Smith TW, ed. Cardiovascular Therapeutics. Philadelphia, Pa: WB Saunders; 1996:427-442.
9. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase. NEJM. 1984;311:1206-1211.
10. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
11. Dutch TIA Trial Study Group. A comparison of two doses of aspirin in patients after a TIA or minor ischaemic stroke. NEJM. 1991;325:1261-1266.
12. Hirsch J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. Chest. 1995;108(Suppl): 247S-257S.
13. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry. 1991;325:1261-1266.
14. Prichard PJ, Kitchingman GK, Walt RP, et al. Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin. Br Med J. 1989;298:493-496.
15. SALT Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet. 1991;33:1345-1349.
16. Kowalski ML. Aspirin sensitive rhinosinusitis and asthma. Allergy Proc. 1995;16: 77-80.
17. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J. 1990;3:588-593.
18. FitzGerald GA. Dipyridamole. NEJM. 1987;316:1247-1257.
19. Rivey MP, Alexander MR, Taylor JW. Dipyridamole: A critical evaluation. Drug Intell Clin Pharm. 1984;18:869-880.
20. Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4:252-261.
21. Noble S, Goa L. Ticlopidine. A review of its pharmacology, clinical efficacy and tolerability in the prevention of cerebral ischemia and stroke. Drugs Aging. 1996;8: 214-232.
22. Schrör K. Antiplatelet drugs. A comparative review. Drugs. 1995;50:7-28.
23. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs. 1995;49:856-878.
24. Ticlid product information. Roche Pharmaceuticals, Nutley, New Jersey, 1997.
25. Lablanche JM, McFadden EP, Bonnet JL, et al. Combined antiplatelet therapy with ticlopidine and aspirin. Eur Heart J. 1996;17:1373-1380.
26. Mills DCB, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb Vasc Biol. 1992;12: 430-436.
27. Coukell A, Markham A. Clopidogrel. Drugs. 1997;54:1-4.
28. Cattaneo M, Lombardi R, Bettega D, et al. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb Vasc Biol. 1993;13:393-397.
29. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348: 1329-1339.
30. Plavix product information. Bristol-Myers Squibb, Princeton, New Jersey, and Sanofi Pharmaceuticals, Inc., New York, New York, March 1997.
31. Genetta TB, Mauro VF. Abciximab: A new antiaggregant used in angioplasty. Ann Pharmacother. 1996;30:251-257.
32. Faulds D, Sorkin EM. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs. 1994;48:583-598.
33. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter trial. Circulation. 1990;82:17-26.
34. Bertrand ME, Allain H, Lablanche JM. Results of a randomized trial of ticlopidine versus placebo for the prevention of acute closure and restenosis after PTCA. The TACT study. Circulation. 1990;82:III-190. Abstract.
35. Chevigné M, David JL, Rigo P, Limet R. Effect of ticlopidine on saphenous vein bypass patency rates: A double-blind study. Ann Thorac Surg. 1984;37: 371-378.
36. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. NEJM. 1994;330: 956-961.
37. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. NEJM. 1997;336: 1689-1696.
38. Gregorini L, Marco J, Fajadet J, et al. Ticlopidine and aspirin pretreatment reduces coagulation and platelet activation during coronary dilation procedures. J Am Coll Cardiol. 1997;29:13-20.
39. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
40. Klimt CR, Knatterud GL, Stamler J, Meir P. Persantine-aspirin reinfarction study II. J Am Coll Cardiol. 1986;7:251-269.
41. Ferguson JJ. Meeting highlights. The 69th Scientific Session of the American Heart Association in New Orleans, La, November 10-13, 1996. Circulation. 1997;95: 761-764.
42. Limet R, David JL, Magotteaux P, et al. Prevention of aorta-coronary bypass graft occlusion. J Thorac Cardiovasc Surg. 1987;94:773-783.
43. Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation. 1980; 62:449-461.
44. Schomig A, Neumann F, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcomes after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol. 1997;29:28-34.
45. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. NEJM. 1980; 323:147-152.
46. White CW, Chaitman B, Knudtson ML, Chrisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: Results from the ticlopidine trial. Coron Artery Dis. 1991;2:757-767.
47. International Stroke Trial Collaborative Group. A randomized trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet. 1997;349:1569-1581.
48. CAST Collaborative Group. CAST: Randomized placebo controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet. 1997;349: 1641-1649.
49. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
50. ESPS Group. The European Stroke Prevention Study (ESPS). Lancet. 1987;2: 1351-1354.
51. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
52. Ticlopidine Aspirin Stroke Study Group. Ticlopidine versus aspirin for stroke prevention: On-treatment results from the ticlopidine aspirin stroke study. J Stroke Cerebrovasc Dis. 1993;3:168-176.
53. Bergqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicenter Study (STIMS). Eur J Vasc Endovasc Surg. 1995;10:69-76.
54. Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: A double-blind placebo-controlled multicenter trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol. 1993;3:523-528.
55. Dettori AG, Pini M, Moratti A, et al. Acenocoumarol and pentoxifylline in intermittent claudication. A controlled clinical study. Angiology. 1989;40:237-248.
56. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays of progression of peripheral occlusive arterial disease. Lancet. 1985;1: 415-419.
57. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Intern Med. 1990;227: 301-308.
58. Lindgarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation. 1989;80:1549-1556.
59. ACC/AHA guidelines of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-1428.
60. Gent M. Benefit of clopidogrel in patients with coronary disease. Circulation. 1997; 96(Suppl):I-467. Abstract.
61. Gent M, Easton JD, Hahinski V, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
62. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994; 308:81-106.
63. Clagett GP, Krupski WC. Antithrombotic therapy in peripheral arterial occlusive disease. Chest. 1995;108(Suppl):431S-443S.
64. Buchanan MR, Brister SJ. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol. 1995;11: 221-227.